Chetchotisakd et al. Materials and Methods
|
|
- Alexis Marsh
- 6 years ago
- Views:
Transcription
1 High Rate Multiple Drug Resistances in HIV-Infected Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Regimens in Thailand, Where Subtype A/E Is Predominant Ploenchan Chetchotisakd, MD, Siriluck Anunnatsiri, MD, Sasisopin Kiertiburanakul, MD, Ruengpung Sutthent, PhD, Thanomsak Anekthananon, MD, Chureeratana Bowonwatanuwong, MD, Boonchai Kowadisaiburana, MD, Khuanchai Supparatpinyo, MD, Manassinee Horsakulthai, MS, Sanchai Chasombat, MD, Kiat Ruxrungtham, MD, and the Study Team The prevalence of drug resistance was determined among 64 HIV-infected Thai patients who were failed while receiving nonnucleoside reverse transcriptase inhibitor (NNRTI) based regimens. Eighty-nine percent of patients had 1 or more NNRTI mutation resistances. Almost all patients had resistance to at least 1 nucleoside reverse transcriptase inhibitor (NRTI), and 42% had multiple-nrti resistance. Keywords: drug resistance in Thailand; NNRTI resistance; NRTI resistance; NNRTI failure Since the introduction of antiretroviral therapy for persons with HIV infection, the rates of mortality and morbidity related to HIV disease have decreased. 1 Current antiretroviral treatment guidelines recommend commencing a combined antiretroviral therapy when a patient has a CD4 count <200 to 350 cells/mm 3 or becomes symptomatic. The preferred first-line combinations are 2 nucleoside reverse transcriptase inhibitors (NRTIs) as a backbone plus either 1 nonnucleoside reverse transcriptase inhibitor (NNRTI) or 1 boosted protease inhibitor (PI). 2,3 Because of the cost and technical issues associated with viral load testing, it is not part of the World Health Organization (WHO) guidelines for antiretroviral therapy (ART) in resource-limited settings. 4 Thus, treatment failure is defined by clinical and immunological criteria 4 ; however, by the time clinical and/or immunological failure is recognized, most patients may have failed virologically for months or even years. Consequently, cumulative resistance-associated mutations will lead to high levels of cross-resistance within the antiretroviral class. There are no data on NNRTI drug resistance with DOI: / Sage Publications Please visit the Journal at the HIV clade A/E, which is the predominant clade in Thailand. Here we report the genotypic resistance pattern in patients with NNRTI-based regimen failure in routine clinical care from various hospitals in Thailand. Materials and Methods Sixty-four HIV-infected adults who had treatment failure after being treated with NNRTI-based regimens for at least 3 months were recruited. Treatment failure is defined as (1) virological failure (ie, the patients had viral load >1000 copies/ml after 3 months of treatment); (2) immunological failure (ie, the CD4 count decreased >30% of the maximum values); and/or (3) clinical failure (ie, the patients developed new or recurrent opportunistic infection after 6 months of therapy). Patients were enrolled between August 2003 and February 2004 from 7 hospitals in Thailand: Srinagarind Hospital, Khon Kaen University (n = 9); Chulalongkorn University Hospital (n = 10); Siriraj Hospital, Mahidol University (n = 11); Ramathibodi Hospital, Mahidol University (n = 9); Bamrasnaradura Institute (n = 9); Chiang Mai University Hospital (n = 10); and Chonburi Hospital (n = 6). The institutional From Srinagarind Hospital, Khon Kaen University, Khon Kaen (Chetchotisakd, Anunnatsiri, and Horsakulthai); Ramathibodi Hospital, Mahidol University, Bangkok (Kiertiburanakul); Siriraj Hospital, Mahidol University, Bangkok (Sutthent and Anekthananon); Chonburi Hospital, Chonburi (Bowonwatanuwong); Bamrasnaradura Institute, Nonthaburi (Kowadisaiburana); Chiang Mai University Hospital, Chiang Mai University, Chiang Mai (Supparatpinyo); Bureau of AIDS, TB, and STI, Department of Disease Control, Ministry of Public Health, Thailand (Chasombat); Chulalongkorn University Hospital, Chulalongkorn University; and the HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok (Ruxrungtham). There are no financial associations of conflicts of interest. Correspondence: Ploenchan Chetchotisakd, Srinagarind Hospital, Khon Kaen University, Khon Kaen 40002, Thailand; ploencha@kku.ac.th. 152 J INT ASSOC PHYSICIANS AIDS CARE 5(4); 2006 pp
2 High Rate Multiple Drug Resistances review board committees of the Thai Ministry of Public Health and each university approved the study. Patients signed a written informed consent. The following were done for each patient: (1) a complete blood cell and CD4 count; (2) an HIV RNA polymerase chain reaction (PCR) with Cobas Amplicor HIV-1 Monitor test, version 1.5 (Roche, Germany); and (3) an HIV-1 genotypic drug resistance assay using the TRUGENE HIV-1 genotyping kit (Visible Genetics, Toronto, Calif). The determination of NRTI mutations was based on the guidelines published by the International AIDS Society United States (IAS-USA) HIV Resistance Testing Guideline Panel Nucleoside analog resistance mutation (NAM) is defined by the presence of any of the following mutations: M41L, E44D, D67N, K70R, V118I, L210W, T215Y/F, or K219Q/E. A greater number of codon mutations (ie, 4) has been found to be associated with cross-resistance with other NRTI except lamivudine (3TC). Resistance to a specific NRTI is defined by the presence of mutations that cause resistance to that particular NRTI. The NNRTI-resistance mutation is defined by the presence of any of the following mutations: L100I, K103N, V106M, Y 181C/I, Y188L, G190S/A, or M230L. Statistical Analysis Descriptive analysis was performed to show the proportions of patients with various NRTI-specific, NNRTIspecific, and multidrug resistance. Factors including the HIV staging, CD4 count, HIV-RNA level, duration of prior ART, NRTI regimen (zidovudine [ZDV], 3TC, didanosine [ddi], or stavudine [d4t]), and prior dual NRTI experience were explored using univariate and multivariate logistic regression (backward logistic regression) analysis to evaluate the association between these factors and any multiple-nrti resistance. Results Of the 64 patients enrolled, 2 were nonevaluable because their samples were not amplifiable by PCR; thus, 62 patients were included in the analysis. The demographic characteristics, HIV disease status, ART data of the cohort, and criteria for treatment failure are presented in Table 1. The majority of patients were AIDS with a median CD4 of 105 cells/mm 3 and a mean HIV-RNA of 4.45 log 10 copies/ml. Most of the patients were receiving their first treatment of an NNRTI-based regimen, which included 3TC, d4t, and nevirapine (NVP). However, 16 patients (26%) received dual NRTI regimens before NNRTI-based regimens. Nevirapine was the most commonly used NNRTI drug (69%). The NRTI backbone for most patients was d4t/3tc (55%), followed by ZDV/ddI Table 1. Demographic Characteristics and HIV Disease Status and Antiretroviral Therapy (ART) Data for a Cohort of 62 HIV-Infected Thai Patients at the Enrollment Value Characteristic n = 62 Age, mean years (SD) 34.9 (6.0) Sex, n (%) Male 36 (58) Female 26 (42) Risk factor of HIV infection, n (%) Heterosexual 58 (94) Intravenous drug abuser 4 (6) HIV disease status, n (%) A 18 (29) B 6 (10) C 38 (61) Median CD4 count, cells/mm 3 (IQR) 105 (30-184) Mean HIV-1 RNA level, log 10 copies/ml (SD) 4.45 (0.81) First ART treatment, n (%) NNRTI-based regimen 46 (74) Prior dual NRTI regimen 16 (26) Type of NNRTI used, n (%)* Nevirapine 43 (69) Efavirenz 21 (34) Type of NRTI used, n (%) Lamivudine 51 (82) Stavudine 49 (79) Zidovudine 21 (34) Didanosine 23 (37) Duration of ART, median weeks (IQR) 145 (84-192) Criteria for treatment failure, n (%) Virological failure 40 (64) Immunological failure 19 (31) Clinical failure 3 (5) IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; ART, antiretroviral therapy. *2 patients had history of previous different NNRTI-based regimen. (17%), ZDV/3TC (13%), d4t/ddi (13%), and ddi/3tc (1%). The median duration of ART was 145 weeks (interquartile range ). The majority of patients experienced treatment failure, as defined by virological criteria (64%). The prevalence of HIV with NNRTI resistance mutations is presented in Table 2. Most of the patients (89%) had 1 or more mutations associated with NNRTI resistance. Mutations at G190S/A and Y181C/I were the most common sites. No mutations at L100I, V106M, and M230L were detected. Mutation at K103N was significantly associated with EFV use, and Y181C/I was associated with NVP use (P =.001). The prevalence of HIV with NRTI resistance is presented in Table 2. Almost all (95%) of patients had at least 1 NRTI resistance associated mutation. The most frequently observed amino acid change was M184V/I, which confers resistance to 3TC (38 of 51 cases exposed to 3TC). Seventy-three percent had at least 1 NAM. Among these mutations, D67N (n = 34) J INT ASSOC PHYSICIANS AIDS CARE 5(4);
3 Table 2. Number of Patients With Specific Mutations by Drug Class and Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Mutation Comparison Between Nevirapine (NVP)-Based and Efavirenz (EFV)-Based Groups NVP-Based EFV-Based Group Overall Group (n = 42) (n = 20) Mutation No. of Patients (%) No. of Patients (%) No. of Patients (%) P Value NNRTI mutation Any NNRTI 55 (89) 36 (86) 19 (95).41 K103N 19 (31) 7 (17) 12 (60).001 Y181C/I 25 (40) 23 (55) 2 (10).001 Y188L 8 (13) 6 (14) 2 (10) 1.00 G190S/A 27 (44) 19 (45) 8 (40).70 1 NNRTI mutation 34 (55) 19 (45) 15 (75).03 >1 NNRTI mutations 21 (34) 17 (41) 4 (20).11 NRTI mutation Any NRTI mutation 59 (95) M41L 21 (34) E44D 5 (8) K65R 11 (18) D67N 34 (55) K70R 20 (32) L74V 3 (5) V118I 13 (21) M184V/I* 38 (61) L210W 17 (27) T215Y/F 25 (40) K219Q/E 17 (27) Q151M complex 7 (11) Any NAM 45 (73) 4 NAMs 20 (32) 4 NAMs and/or Q151M 26 (42) NAM, nucleoside analog resistance mutation. NAMs include M41L, E44D, D67N, K70R, V118I, L210W, T215Y/F, and K219Q/E mutations. *75% (38/51 cases) among lamivudine-experienced patients. % of patients No mutation Figure NNRTI 61 3TC 95 Any NRTI was the most common, followed by T215Y/F, M41L, and K70R, respectively. Thirty-two percent of the 73 Any NAMs 32 >/=4NAMs 11 Q151M 42 MDR-NRTI Prevalence of HIV with nonnucleoside reverse transcriptase inhibitor (NNRTI) and nucleoside reverse transcriptase inhibitor (NRTI) resistance among 62 HIV-infected patients. NNRTI-resistance mutation included L100I, K103N, V106M, Y 181C/I, Y188L, G190S/A, and M230L. Nucleoside analog resistance mutations (NAMs) included M41L, E44D, D67N, K70R, V118I, L210W, T215Y/F, and K219Q/E mutations. 3TC, lamivudine-resistance mutations (M184V/I) and Q151M, the multidrug-resistance mutation. MDR- NRTI, the multiple-nrti-drug resistance, the combination of patients with 4 NAMs and/or Q151M. patients had 4 NAMs. Only 3 patients had a didanosinespecific mutation (L74V). None of the patients had HIV with multiple-nrti-resistance 69-insertion complex. When patients with 4 NAMs and/or Q151M were considered, 42% had multiple-nrti resistance. M184V/ I mutation was found only in patients who had received 3TC. Seven patients had Q151M multidrug-resistance mutation. The prevalence of HIV with NNRTI, 3TC, NRTI, and multidrug-resistance-nrti among 62 HIVinfected patients is summarized in Figure 1. In multivariate analysis, adjusted for HIV staging, the HIV RNA level, the CD4 count, the duration of treatment with antiretroviral (ARV) medications, NRTI regimens, and prior dual NRTI experience, only ddi exposure was significantly related to Q151M mutation (odds ratio [OR] 22.82; 95% confidence interval [CI] ; P =.01). The presence of 4 NAMs was significantly related to the duration of ARV medication exposure >96 weeks (OR 5.54; 95% CI ; P =.035), advances HIV infection (OR 5.54; 95% CI ; P =.035), and high baseline viral load (OR 2.84; 95% CI ; P =.01). In multivariate analysis, adjusted for HIV staging, the HIV RNA level, CD4 count, duration of ART, NRTI regimens, and prior dual NRTI experience, 154 J INT ASSOC PHYSICIANS AIDS CARE 5(4); 2006
4 High Rate Multiple Drug Resistances only the duration of ARV medication exposure >96 weeks (OR 6.29; 95% CI ; P =.042) and high baseline HIV-RNA (OR 3.92; 95% CI ; P =.011) were significantly associated with the presence of 4 NAMs. Discussion Our study shows that the majority of patients who experienced treatment failure while receiving NNRTIbased regimens had HIV with both NNRTI and NRTI mutations. Eighty-nine percent of the patients had NNRTI mutations, which conferred resistance to the entire NNRTI drug class. Among the NRTI mutations, 61% had M184V and 73% had HIV with NAMs, which conferred cross-resistance among NRTIs. Infection with HIV with 4 NAMs and Q151M was associated with resistance to all NRTIs. Forty-two percent of the patients in our study had HIV with 4 NAMs and/or Q151M, and, as a consequence, the likelihood of treatment with new NRTIs having adequate viral suppressive effect was poor. In addition, in the majority of patients receiving 3TC-based regimens (75%), mutations conferring 3TC resistance were very common, further limiting the choice of NRTIs. It is unlikely that such patients can be salvaged with the 2 new NRTIs plus boosted PI, as recommended by the guidelines. 6 Our study also confirmed other reports that crossresistance to both ZDV and d4t, by selecting and accumulating NAMs, is almost universal Interestingly, 3 of our patients with the L74V mutation, which conferred resistance to ddi, did not receive ddi as part of the treatment regimen before (data not shown). However, the use of ddi was associated with Q151M, a multidrugresistant mutation, and HIV with the multiple-nrtiresistance 69-insertion complex was not detected. These findings concur with 2 other Thai studies. 8,10 Sixteen patients in the cohort were switched from dual NRTIs (ie, ZDV/ddI, ZDV/3TC, d4t/3tc, or d4t/ddi) to NNRTI-based regimens. Among these patients, NAMs might have already been selected before switching, 7-10 resulting in rapid virological failure attributable to the emergence of NNRTI resistance. A fixed-dose combination of d4t/3tc/nvp was the most commonly used in this cohort. Evidence indicates that NNRTI resistance tends to develop during drug holiday because NVP and EFV have a much longer halflife than NRTIs, resulting in a de facto monotherapy. 11 Lamivudine resistance will consequentially be developed after reinitiation of the medication because the regimen relies on dual NRTIs. As we demonstrated, the longer patients are on this inadequate regimen, the greater the accumulation of NAMs. As evidenced by our multivariate analysis, patients who experienced treatment for longer than 96 weeks were associated with the presence of 4 NAMs (OR 6.29; 95% CI ; P =.042). The NRTI mutation seen in this cohort was not different from mutations in patients infected with the HIV clades A, B, C, and F. 8-10,12,13 Of interest, for NNRTI mutations, the most common mutation was G190S/A. By comparison, with the HIV clades A, C, and D, the most common mutation was K103N. 14,15 However, we found that K103N was associated with EFV use and Y181C/I was associated with NVP use similar to HIV clade B. 15 Fixed-dose combinations of 3TC/d4T/NVP and ZDV/3TC/NVP are currently available in Thailand. In our study, a fixed-dose combination of 3TC/d4T/NVP called GPO-VIR was the commonly used. Similar fixeddose combinations of these drugs are also available in Africa and India. These drugs potentially serve as a prime choice for ART in resource-limited settings because of the low price, low drug interaction, and low incidence of long-term side effect on lipids. NVP demonstrated a similar efficacy compared with EFV in the 2NN Study. 16 Early cutaneous side effects and hepatotoxicity can be managed by careful monitoring and initiation with lead-in fashion. Hepatoxicity is less common in patients with low CD4 count, which are the major population of ART initiators in resourcepoor settings. However, combining drugs that have a low resistance threshold, such as 3TC and NVP, would likely result in treatment failure among noncompliant patients. With increasing use of ART, in accordance with the WHO s 3 by 5 Initiative Campaign, more patients with drug resistance are inevitable, especially without viral load testing. The present study provides an important message on the high prevalence of HIV with NNRTI and 3TC resistance mutations in patients treated with NNRTIbased regimens that include 3TC as the NRTI backbone; we also demonstrated the high prevalence of 4 NAMs in patients who had been on ARV medication for longer than 96 weeks and those who had a high baseline viral load. Hence, there are very limited options regarding new and effective NRTIs for the salvage regimen in these situations. Affordable and appropriate salvage regimens for patients who fail NNRTIbased therapy in resource-limited countries need further investigation in a large clinical trial. Therefore, wide implementation of effective and practical measures to encourage treatment adherence is the most critical challenge for this important global treatment access program. Aggressive effort is needed to make a low-cost viral load assay available for resource-poor settings, to enable early detection of virological failure, and to prevent development of cross-resistance viruses. J INT ASSOC PHYSICIANS AIDS CARE 5(4);
5 Acknowledgments We thank the patients for their participation, professors Surapol Suwannakul and Praphan Phanuphak for their advice and support, and Mr. Bryan Roderick Hamman for assistance with the English-language presentation. Study Team Piroon Mootsikapun and Parichat Seawsirikul, Srinagarind Hospital, Khon Kaen University, Khon Kaen; Bucha Piyavong, Ramathibodi Hospital, Mahidol University, Bangkok; Winai Ratanasuwan, Wichai Techasathit, Nitaya Chuengprasert, and Daungnapha Aeworn, Siriraj Hospital, Mahidol University, Bangkok; Nophanath Chumpathat, Patamavadee Termvises, and Suphida Thongyen, Bamrasnaradura Institute, Nonthaburi; Romanee Chaiwarith, Chiang Mai University Hospital, Chiang Mai University, Chiang Mai; Somyot Kittimunkong, Bureau of AIDS, TB, and STI, Department of Disease Control, Ministry of Public Health, Thailand; and Chris Dumcomb and Jiranan Sewatatat, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok. Financial Support Provided through a grant from the Bureau of AIDS, TB, and STI, Department of Disease Control, Ministry of Public Health, Thailand. Potential Conflicts of Interest Kiat Ruxrungtham and Thanomsak Anekthananon received research grant support from the Government Pharmaceutical Organization (GPO), which manufactures GPO VIR. References 1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338: Gazzard B, BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med. 2005;6(suppl 2): Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents. DHHS Panel on Clinical Practice for Treatment of HIV infection. Available at: Accessed April 7, WHO. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. Geneva: WHO; Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Top HIV Med. 2005; 13: Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292: Maxeiner HG, Keulen W, Schuurman R, et al. Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients. J Infect Dis. 2002;185: Sirivichayakul S, Ruxrungtham K, Ungsedhapand C, et al. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse-transcriptase inhibitors. AIDS. 2003;17: van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1-infected children. Lancet Infect Dis. 2002;2: Lolekha R, Siangphoe U, Pancharoen C, et al. Resistance to dual nucleoside reverse transcriptase inhibitors in children infected with HIV clade A/E. Clin Infect Dis. 2005;40: Taylor S, Allen S, Fidler S, et al. Stop study: after discontinuation of efavirenz, plasma concentrations may persist for 2 weeks or longer. Paper presented at: 11th CROI; February 2004; San Francisco, Calif. 12. de Mendoza C, Ramos JT, Ciria L, et al. Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter. HIV Clin Trials. 2002;3: Pellegrin I, Izopet J, Reynes J, et al. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group. AIDS. 1999;13: Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in woman with HIV-1 subtype C, compared with subtypes A and D after the administration of single-dose NVP. J Infect Dis. 2005;192: Grossman Z, Istomin V, Averbuch D, et al. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS. 2004;18: van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363: J INT ASSOC PHYSICIANS AIDS CARE 5(4); 2006
HIV-1 DRUG RESISTANCE MUTATIONS IN CHILDREN WHO FAILED NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY
HIV-1 DRUG RESISTANCE MUTATIONS IN CHILDREN HIV-1 DRUG RESISTANCE MUTATIONS IN CHILDREN WHO FAILED NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY Somnuek Sungkanuparph 1, Nopporn
More informationThe widespread use of antiretroviral therapy (ART) for the
ORIGINAL STUDIES Predictors of Virologic Failure and Genotypic Resistance Mutation Patterns in Thai Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor Based Antiretroviral Therapy Podjanee
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationRole of Efavirenz in HIV-infected Patients with Preceding Nevirapine-related Skin Rash
Review Article Vol. 24 No. 2 Nevirapine-associated rashes:- Manosuthi W & Sungkanuparph S. 89 Role of Efavirenz in HIV-infected Patients with Preceding Nevirapine-related Skin Rash Weerawat Manosuthi,
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationGenotypic Resistance in HIV-infected Patients Failing a d4t/3tc/nvp Regimen
Original Article Genotypic Resistance in HIV-infected Patients Failing a d4t/3tc/nvp Regimen Somnuek Sungkanuparph, M.D.* Weerawat Manosuthi, M.D.* Sasisopin Kiertiburanakul, M.D.* Wasun chantratita, Ph.D.**
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationPerspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation
Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Resistance testing has emerged as an important tool for antiretroviral management. Research continues to refine
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationSupplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study
Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Study Almeida 2011 Auld 2011 Bassett 2012 Bastard 2012 Boulle 2008 (a) Boulle 2008 (b) Boulle 2010 Breen
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationPRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES
PRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES Mark A. Wainberg McGill University AIDS Centre Jewish General Hospital Montreal, Quebec,
More informationAttrition and Treatment Outcomes among Perinatally and Behaviourally HIV-infected Adolescents and Youths in Thai National AIDS program
Attrition and Treatment Outcomes among Perinatally and Behaviourally HIV-infected Adolescents and Youths in Thai National AIDS program Sirinya Teeraananchai 1,2, Thanyawee Puthanakit 1,3,4, Suchada Chaivooth
More informationNOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationTreatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand
Treatment experience in South Africa Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Overview South African Prevalence Adherence Combination ddi + d4t Nevirapine Hepatotoxicity
More informationCryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease
Cryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease Assist Prof. Somnuek Sungkanuparph Division of Infectious Diseases Faculty of Medicine Ramathibodi Hospital Mahidol
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationHighly active antiretroviral (ARV) therapy (HAART) has dramatically
ORIGINAL STUDIES Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral
More informationApatcha Pungjitprapai, M.D., Mattana Hanvanich, M.D. Abstract of Infectious Diseases Fellows
of Infectious Diseases Fellows A Study of Plasma HIV RNA Viral Load Response to the Treatment with Low Dose Stavudine (D4T) in Lamivudine (3TC) and Efavirenz Containing Highly Active Antiretroviral Regimen
More informationNNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington Last Updated:
More informationOriginal Article. Noparat Oniem, M.D., Somnuek Sungkanuparph, M.D.
Original Article Vol. 29 No. 1 Primary prophylaxis for cryptococcosis with fluconazole:- Oniem N & Sungkanuparph S. 5 Primary prophylaxis for cryptococcosis with fluconazole among HIV-infected patients
More informationEvaluation and Management of Virologic Failure
National HIV Curriculum PDF created November 3, 2018, 12:26 am Evaluation and Management of Virologic Failure This is a PDF version of the following document: Section 1: Antiretroviral Therapy Topic 5:
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationHistory (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11
(August 2010) Therapy for Experienced Patients Hiroyu Hatano, MD, MHS Assistant Professor of Medicine University of California San Francisco Medical Management of AIDS December 2011 42M HIV (CD4=450, VL=6250,
More informationKirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia 3
Antiviral Therapy 2011; 16:1113 1121 (doi: 10.3851/IMP1906) Original article Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase
More informationAntiviral Therapy 2012; 17: (doi: /IMP2443)
Antiviral Therapy 2012; 17:1351 1361 (doi: 10.3851/IMP2443) Original article A randomized comparison of second-line lopinavir/ ritonavir monotherapy versus tenofovir/lamivudine/ lopinavir/ritonavir in
More informationSpecial Contribution Questions to and Answers from the International AIDS Society USA Resistance Testing Guidelines Panel
Special Contribution Questions to and Answers from the International AIDS Society USA Resistance Testing Guidelines Panel In 1996 the International AIDS Society USA convened an international panel of experts
More informationDrug resistance is widespread among children who receive long-term antiretroviral treatment at a rural Tanzanian hospital
J Antimicrob Chemother 2010; 65: 1996 2000 doi:10.1093/jac/dkq234 Advance Access publication 24 June 2010 Drug resistance is widespread among children who receive long-term antiretroviral treatment at
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationCLINICALLY SIGNIFICANT DRUG INTERACTIONS AMONG HIV-INFECTED PATIENTS RECEIVING ANTIRETROVIRAL THERAPY
CLINICALLY SIGNIFICANT DRUG INTERACTIONS AMONG HIV-INFECTED PATIENTS RECEIVING ANTIRETROVIRAL THERAPY Apichot So-Ngern 1, Preecha Montakantikul 2 and Weerawat Manosuthi 3 1 Faculty of Pharmacy, Siam University,
More informationInteractive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1
Antiviral Therapy 10:551 555 Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1 Mina John, Corey B Moore, Ian R James and Simon A Mallal* Centre for Clinical
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationPharmacovigilance of highly active antiretroviral therapy among adult patients in a large urban HIV treatment center in Nigeria
Abstract no. A-641-0120-07827 Pharmacovigilance of highly active antiretroviral therapy among adult patients in a large urban HIV treatment center in Nigeria I.O. Abah 1, P. Ugoagwu, V. Ojeh, L. Ogwuche,
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More information18 July 2009 The 1st International Workshop on HIV Pediatrics Cape Town, South Africa
A Novel Pediatric Fixed-Dose Combination (FDC) of Zidovudine (ZDV), Lamivudine (3TC), Nevirapine (NVP): Pharmacokinetics and Safety in HIV-Infected Thai Children 18 July 2009 The 1st International Workshop
More informationFrailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi
Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:
More informationEfficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children
International Journal of Infectious Diseases (2008) 12, e33 e38 http://intl.elsevierhealth.com/journals/ijid Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHIV Drug Resistance among Adolescents and Young Adults Failing HIV Therapy in Zimbabwe
HIV Drug Resistance among Adolescents and Young Adults Failing HIV Therapy in Zimbabwe V Kouamou 1, J Manasa 1, D Katzenstein 1, A McGregor 1, CE Ndhlovu 1 & AT Makadzange 1. 1 University of Zimbabwe Introduction
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationThe Danish HIV Cohort Study, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark 4
Antiviral Therapy 2009 14: 995 1000 (doi: 10.3851/IMP1412) Original article The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish
More informationWhole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy
Whole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy K El Bouzidi 1,, RP Datir 1, V Kwaghe 3, S Roy 1, D Frampton
More informationClinical skills building - HIV drug resistance
Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)
More information10 : 4. Introduction. R Sajithkumar, Kottayam. Mutations to select agents: Evolution:
10 : 4 HIV drug resistance and second line of ART Introduction The first response to the HIV epidemic identified as AIDS in 1981- was the feeling of helplessness. The cause of the illness was soon identified
More informationWHO MODEL LIST OF ESSENTIAL MEDICINES APPLICATION. stavudine/lamivudine/nevirapine fixed-dose combination tablets for the treatment of HIV-1 infection
WHO MODEL LIST OF ESSENTIAL MEDICINES APPLICATION stavudine/lamivudine/nevirapine fixed-dose combination tablets for the treatment of HIV-1 infection 1. Summary statement of proposal for inclusion, change,
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationSupersensitive Viral Load Assay in Predicting CD4-Guided Treatment Failure
The Open Virology Journal, 2008, 2, 69-73 69 Open Access Supersensitive Viral Load Assay in Predicting CD4-Guided Treatment Failure Simone Langford a,, Angele Gayet-Ageron b,, Chris Duncombe a, Thidarat
More informationTransient viral load increases in HIV-infected children in the UK and Ireland: what do they mean?
Transient viral load increases in HIV-infected children in the UK and Ireland: what do they mean? Katherine J Lee 1 *, Delane Shingadia 2, Deenan Pillay 3, A Sarah Walker 1, Andrew Riordan 4, Esse Menson
More informationAIDS, antiretroviral drugs, human immunodeficiency virus, mutations, pol gene, resistance
ORIGINAL ARTICLE Peptide insertions in reverse transcriptase pol gene of human immunodeficiency virus type 1 as a rare cause of persistent antiretroviral therapeutic failure Véronique Schneider 1,Jérôme
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationAntiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa
Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa Alana T Brennan, Kate Shearer, Mhairi Maskew, Prudence Ive, Ian Sanne, Matthew P Fox Health Economics
More informationORIGINAL ARTICLE /j x. Brescia, Italy
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.00938.x Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive
More informationLiver Toxicity in Epidemiological Cohorts
SUPPLEMENT ARTICLE Liver Toxicity in Epidemiological Cohorts Stephen Becker Pacific Horizon Medical Group, San Francisco, California Hepatotoxicity has been demonstrated to be associated with antiretroviral
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More information14 TH EUROPEAN HIV & HEPATITIS MEETING Abst#_O_06
14 TH EUROPEAN HIV & HEPATITIS MEETING 2016 Abst#_O_06 Patients with pre-existent NRTI- and NNRTI-resistance have a higher risk to lose virological suppression under tenofovir/emtricitabine/rilpivirine
More informationReverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review
pissn 2349-2910 eissn 2395-0684 REVIEW Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review Dinesh Bure, Department
More informationSURVEILLANCE OF HIV-1 DRUG-RESISTANCE MUTATIONS IN THAILAND FROM 1999 TO 2014
SURVEILLANCE OF HIV-1 DRUG-RESISTANCE MUTATIONS IN THAILAND FROM 1999 TO 2014 Nareenart Iemwimangsa 1, Ekawat Pasomsub 1, Chonlaphat Sukasem 2 and Wasun Chantratita 1 1 Division for Virology, 2 Division
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationHIV/AIDS CID 2003:37 (1 July) 113
MAJOR ARTICLE HIV/AIDS Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society USA Panel Martin S. Hirsch,
More informationCase Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital.
Case Study Dr Sarah Sasson Immunopathology Registrar HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital Case 1: Case 1: 45F in Cameroon Cameroon HIV+ Presents with cutaneous
More informationThe availability and cost are obstacles to using pvl in monitoring HIV treatment outcomes in resource-constrained settings
Impact of the frequency of plasma viral load monitoring on treatment outcome among perinatally HIVinfected Asian children stable on first-line NNRTI-based cart T Sudjaritruk, DC Boettiger, NV Lam, KAM
More informationAntiviral Therapy 2013; 18: (doi: /IMP2329)
Antiviral Therapy 2013; 18:213 219 (doi: 10.3851/IMP2329) Original article Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the
More informationReasons for Anti-Retroviral Regimen Changes in HIV/AIDS patients of Ayder Referral Hospital ART clinic, Mekelle, Ethiopia.
Reasons for Anti-Retroviral Regimen Changes in HIV/AIDS patients of Ayder Referral Hospital ART clinic, Mekelle, Ethiopia. LEMLEM GEBREMEDHIN *, AMANUEL BIRHANE 2, 2 Pharmacology and Toxicology course
More informationHIV Drug Resistance: An Overview
Human Journals Review Article October 2015 Vol.:1, Issue:1 All rights are reserved by Suraj Narayan Mali et al. HIV Drug Resistance: An Overview Keywords: HIV drug resistance mechanism, Antiretroviral
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationHIV Clinical Management: Antiretroviral Therapy and Drug Resistance
HIV Clinical Management: Antiretroviral Therapy and Drug Resistance Judith S. Currier, MD, MSc Professor of Medicine University of California, Los Angeles Disclosures: Research Grant from Theratechnologies
More informationOriginal article Life expectancy after initiation of combination antiretroviral therapy in Thailand
Antiviral Therapy 2017; 22:393 402 (doi: 10.3851/IMP3121) Original article Life expectancy after initiation of combination antiretroviral therapy in Thailand Sirinya Teeraananchai 1,2 *, Suchada Chaivooth
More informationVitamin D Deficiency in HIV: A Shadow on Long-Term Management?
AIDS Rev. 2014;16:59-74 (Supplementary Data) Vitamin D Deficiency in HIV: A Shadow on Long-Term Management? Chloe Orkin, et al.: Vitamin D deficiency in HIV (Supplementary Data) Chloe Orkin 1, David A.
More informationEvolving Realities of HIV Treatment in Resource-limited Settings
Evolving Realities of HIV Treatment in Resource-limited Settings Papa Salif Sow MD, MSc Department of Infectious Diseases University of Dakar, Senegal Introduction: ARV access in RLS Scale-up of ART has
More informationDr Marta Boffito Chelsea and Westminster Hospital, London
Dr Marta Boffito Chelsea and Westminster Hospital, London Speaker Name Statement Dr Marta Boffito has received travel and research grants from and has been an advisor for Janssen, Roche, Pfizer, ViiV,
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationAntiviral Therapy 2011; 16: (doi: /IMP1851)
Antiviral Therapy 2011; 16:925 929 (doi: 10.3851/IMP1851) Short communication Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationDrug-Selected Resistance Mutations and Non-B Subtypes in Antiretroviral-Naive Adults with Established Human Immunodeficiency Virus Infection
MAJOR ARTICLE Drug-Selected Resistance Mutations and Non-B Subtypes in Antiretroviral-Naive Adults with Established Human Immunodeficiency Virus Infection George J. Hanna, 1,a Henri U. Balaguera, 2,a Kenneth
More informationVirologic and CD4 Cell Response to Zidovudine or Zidovudine and Lamivudine Following Didanosine Treatment of Human Immunodeficiency Virus Infection
AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 17, Number 3, 2001, pp. 203 210 Mary Ann Liebert, Inc. Virologic and CD4 Cell Response to Zidovudine or Zidovudine and Lamivudine Following Didanosine Treatment
More informationPersistent low-level HIV-1 RNA between 20 and 50 copies/ml in antiretroviral-treated patients: associated factors and virological outcome
J Antimicrob Chemother 2012; 67: 2231 2235 doi:10.1093/jac/dks191 Advance Access publication 29 May 2012 Persistent low-level HIV-1 RNA between 20 and 50 copies/ml in antiretroviral-treated patients: associated
More informationHIV DRUG RESISTANCE IN AFRICA
HIV DRUG RESISTANCE IN AFRICA Francis Ssali Joint Clinical Research Centre, Kampala Interest Meeting Mombasa May 10 th 2012 Scope 1. HIV-DR testing in Africa 2. The Epidemiology of HIV-DR in Africa 3.
More informationTreatment of HIV-1 in Adults and Adolescents: Part 2
Treatment of HIV-1 in Adults and Adolescents: Part 2 Heather E. Vezina, Pharm.D. University of Minnesota Laboratory Medicine & Pathology Experimental & Clinical Pharmacology wynnx004@umn.edu Management
More informationStructured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007
Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection
More informationTHE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner
More informationAcquired HIV Drug Resistance in children in Asia
Acquired HIV Drug Resistance in children in Asia Jintanat Ananworanich, MD, PhD Pediatrician/Immunologist Deputy Director in Scientific Affairs, HIV-NAT Chief, SEARCH The Thai Red Cross AIDS Research Centre
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationSocio-Demographic Factors associated with Success of Antiretroviral Treatment among HIV Patients in Tanzania
Socio-Demographic Factors associated with Success of Antiretroviral Treatment among HIV Patients in Tanzania Dr. Fausta Franklin Mosha (MD, MSc, MSc, PHD) Ministry of Health and Social Welfare 22 nd October
More informationTreatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens
Send Orders for Reprints to reprints@benthamscience.ae 38 The Open AIDS Journal, 2015, 9, 38-44 Open Access Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing
More informationResearch Article Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors
Hindawi BioMed Research International Volume 2017, Article ID 7481597, 14 pages https://doi.org/10.1155/2017/7481597 Research Article Metabolic Disorders in HIV-Infected Adolescents Receiving Protease
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationManagement of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More informationThe Lipid-Lowering Efficacy of Switching Within Non-Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients
American Journal of Infectious Diseases 4 (2): 147-151, 2008 ISSN 1553-6203 2008 Science Publications The Lipid-Lowering Efficacy of Switching Within Non-Nucleoside Reverse Transcriptase Inhibitors in
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationHepatitis B Case Studies
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No
More information